14.07
14.07 (0%)
As of Apr 17, 2025
Keros Therapeutics, Inc. [KROS]
Source:
Company Overview
Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta, or TGF- , family of proteins. We are a leader in understanding the role of the TGF- family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue.
| Country | United States |
| Headquarters | lexington, massachusetts |
| Phone Number | 617-314-6297 |
| Industry | manufacturing |
| CEO | Jasbir Seehra, Ph.D. |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $3.6 |
| Operating Profit | $-210.8 |
| Net Income | $-187.4 |
| Net Cash | $229 |
Profit Ratios
| Gross Margin | $3.6 |
| Operating Margin | -5,939 |
| Profit as % of Revenues | -1.9% |
| Profit as % of Assets | -38% |
| Profit as % of Stockholder Equity | -32.8% |
Management Effectiveness
| Return on Equity | -32.8% |
| Return on Assets | -30.4% |
| Turnover Ratio | 0.7% |
| EBITA | $-210.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $615.9 |
| Total Liabilities | $44.3 |
| Operating Cash Flow | $-160.9 |
| Investing Cash Flow | $-1.9 |
| Financing Cash Flow | $391.8 |
